We are taking the threat of COVID-19 very seriously. Click here to find out what our firm is doing.
Free Injury ConsultationCall for family law consultation rates
(800) 811-9495(919) 661-9000Español
Español Tap to Call(800) 811-9495

Why did the FDA require a change to the Zyprexa label?

In September 2003, the U.S. Food and Drug Administration (FDA) ordered Eli Lilly to revise the Zyprexa® labeling and product information to inform doctors and patients that the use of Zyprexa® (and other SGAs) has been associated with an increased risk of glucose abnormalities and diabetes. On March 1, 2004, Eli Lilly issued a “Dear Doctor” letter to individual physicians in which it informed doctors of the increased risk of hyperglycemia and diabetes in patients taking Zyprexa® and described the label changes.

About the Author

Awards & Memberships